Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Fresenius    FRE   DE0005785604

FRESENIUS (FRE)

Real-time Quote. Real-time Tradegate - 06/23 05:21:15 pm
78.286 EUR   -0.83%
11:59a FRESENIUS : wins award for Quirónsalud acquisition
06/20FRESENIUS : Technically solid
06/01 FRESENIUS : Danvers Police Department announced Friday that an asses..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Fresenius Sets Pricing On EUR500 Million 7-Year Bond At 4.25% Area

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/21/2012 | 01:24pm CEST

("Fresenius Sets Pricing On EUR500M 7-Year Bond At 4.25% Area," at 1020 GMT, misstated the vehicle issuing the bond in the first paragraph. The correct version follows:)

-German medical care company Fresenius SE & CO. KGaA (>> Fresenius SE & Co KGaA) has set price guidance on its EUR500 million seven-year bond in the area of 4.25%, one of the banks on the deal said Wednesday.

The issue will be priced later Wednesday, and books on the deal are comfortably oversubscribed, said one of the banks on the deal. The issue was primarily targeted at retail accounts, which showed a good deal of interest, it added.

The bond will be used--among other corporate purposes--to fund the acquisition of hospital operator Damp Group, which Fresenius acquired in October 2011.

Expected ratings are Ba1 from Moody's Investors Service and BB+ from Standard & Poor's Corp. and Fitch Ratings.

Royal Bank of Scotland Group PLC, Deutsche Bank AG, Commerzbank AG, LBBW and Bayern LB are lead managers on the deal.

-By Serena Ruffoni, Dow Jones Newswires; +44 (0) 207 842 9349; [email protected]

Stocks mentioned in the article : Fresenius SE & Co KGaA
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on FRESENIUS
11:59a FRESENIUS : wins award for Quirónsalud acquisition
06/22 FRESENIUS : Patent Issued for Composition Comprising a Combination of DHA and EP..
06/15 FRESENIUS : Patent Issued for Stable Pharmaceutical Composition of 5-Aza-2'-Deox..
06/09 FRESENIUS : Patent Issued for Methods for Analysis of Protamine (USPTO 9664685)
06/07 DGAP-DD : Fresenius SE & Co. KGaA english
06/01 FRESENIUS : Danvers Police Department announced Friday that an assessment team w..
06/01 FRESENIUS : POLICE accreditation Public invited to comment
06/01 SECTOR 5 : Protocol cars
05/31 DGAP-NVR : Fresenius SE & Co. KGaA: Release according to Article 26a of the WpHG..
05/30 EXCLUSIVE - MALLINCKRODT EXPLORES SA : sources
More news
Sector news : Hospitals, Clinics & Primary Care Services
06/01 FTSE flirts with record level though sterling boost fades; Inmarsat jumps
05/24 FTSE edges up helped by M&S, but miners weigh
05/24 Middle East rules hurts South Africa's Mediclinic earnings
05/19DJIHH HEALTHCARE BHD : Malaysia's IHH Healthcare 1Q Net Profit Rises
04/28 Four tales of the Trump trade, 100 days into his presidency
More sector news : Hospitals, Clinics & Primary Care Services
News from SeekingAlpha
06/13 Fresenius SE & Co. KGaA (FSNUF) Presents At Goldman Sachs 38th Annual Global ..
06/08 The 2017 Update Of The German Dividend Aristocrats
05/22 Fresenius SE & Co. KGaA (FSNUF) Presents At BofAML 2017 Healthcare Conference
05/06 Fresenius SE & Co. KGaA's (FSNUY) Management on Q1 2017 Results - Earnings Ca..
04/26 Fresenius Shows Biotech How To Get The Deals Done
Advertisement
Financials (€)
Sales 2017 34 378 M
EBIT 2017 5 058 M
Net income 2017 1 893 M
Debt 2017 15 609 M
Yield 2017 0,94%
P/E ratio 2017 23,21
P/E ratio 2018 20,99
EV / Sales 2017 1,73x
EV / Sales 2018 1,58x
Capitalization 43 724 M
More Financials
Chart FRESENIUS
Duration : Period :
Fresenius Technical Analysis Chart | FRE | DE0005785604 | 4-Traders
Full-screen chart
Technical analysis trends FRESENIUS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 81,6 €
Spread / Average Target 3,4%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Stephan Sturm President & Chief Executive Officer
Niko Stumpfögger Member-Supervisory Board
Klaus-Peter Müller Member-Supervisory Board
Rainer Stein Member-Supervisory Board
Michael Albrecht Member-Supervisory Board
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
FRESENIUS6.30%48 819
IHH HEALTHCARE BHD--.--%11 523
RAMSAY HEALTH CARE LIM..5.56%10 972
BANGKOK DUSIT MEDICAL ..--.--%8 669
MEDICLINIC INTERNATION..0.45%7 252
ENVISION HEALTHCARE CO..-4.72%7 087
More Results